N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide

• ChemBase编号: 837
• 分子式: C15H22N2O
• 平均质量: 246.34798
• 单一同位素质量: 246.17321333
• SMILES: O=C(Nc1c(cccc1C)C)C1N(CCCC1)C
• Canonical SMILES: CN1CCCCC1C(=O)Nc1c(C)cccc1C
• InChI: InChI=1S/C15H22N2O/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18)
• InChIKey: INWLQCZOYSRPNW-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide
• IUPAC传统名: mepivacaine
• 商标名: Arestocaine HCL; Carbocain; Carbocaine; Isocaine HCL; Polocaine; Polocaine-MPF; Scandicain; Scandicaine; Scandicane; Scandonest Plain
• 别名: Mepivacaina [INN-Spanish]; DL-Mepivacaine; Mepivacaine HCL; mepivacaine hydrochloride; Mepivacainum [INN-Latin]; Mepivicaine; S-Ropivacaine Mesylate; Mepivacaine; N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamide

登记号

• CAS号: 96-88-8
• MDL号: MFCD00243006
• PubChem SID: 46507857; 160964300
• PubChem CID: 4062

理论计算性质

JChem

• Acid pKa: 13.623901
• 质子受体: 2
• 质子供体: 1
• LogD (pH = 5.5): 1.4378594
• LogD (pH = 7.4): 2.9576306
• Log P: 3.1916199
• 摩尔折射率: 76.3197 cm^3
• 极化性: 28.751305 Å^3
• 极化表面积: 32.34 Å^2
• 可自由旋转的化学键: 2
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 2.16
• LOG S: -2.6
• 溶解度: 6.21e-01 g/l

分子性质

理化性质

• 溶解度: Soluble (7000 mg/L)
• 疏水性(logP): 2.2

产品相关信息

• 纯度: 95+%

详细说明

DrugBank - DB00961

• Drug Groups: approved
• Description: A local anesthetic that is chemically related to bupivacaine but pharmacologically related to lidocaine. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168)
• Indication: For production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks.
• Pharmacology: Mepivicaine is a local anesthetic of the amide type. Mepivicaine as a reasonably rapid onset and medium duration and is known by the proprietary names as Carbocaine and Polocaine. Mepivicaine is used in local infiltration and regional anesthesia. Systemic absorption of local anesthetics produces effects on the cardiovascular and central nervous systems. At blood concentrations achieved with normal therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal.
• Toxicity: The mean seizure dosage of mepivacaine in rhesus monkeys was found to be 18.8 mg/kg with mean arterial plasma concentration of 24.4 µg/mL. The intravenous and subcutaneous LD 50 in mice is 23 mg/kg to 35 mg/kg and 280 mg/kg respectively.
• Affected Organisms: Humans and other mammals
• Biotransformation: Rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine. The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites.
• Absorption: Absorbed locally. The rate of systemic absorption of local anesthetics is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic solution.
• Half Life: The half-life of mepivacaine in adults is 1.9 to 3.2 hours and in neonates 8.7 to 9 hours.
• Protein Binding: Mepivacaine is approximately 75% bound to plasma proteins. Generally, the lower the plasma concentration of drug, the higher the percentage of drug bound to plasma.
• Elimination: It is rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine.The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites.
• External Links: Wikipedia; RxList; Drugs.com